Compare Cassava Sciences Inc (FLNA) vs KeyCorp (KEY) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

KeyCorp (KEY) trades at $23.96, up 2.83% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.44 exceeding the $0.4135 estimate. Fundamentals are solid, with a P/E of 14.44 and net income margin of 26.05% for 2025. Recent news highlights dividend declarations and strategic partnerships, reinforcing positive momentum.

The outlook for KEY is favorable, driven by earnings growth and a $3 billion buyback program. Risks include interest rate sensitivity and competitive pressures. With a consensus price target of $29.32, upside potential exists, but investors should monitor economic conditions affecting regional banks.